From Israel, Macau and South Korea
Suven Life Sciences announced that it has secured one (1) product patent from Israel (236437), one (1) product patent from Macau (J/002376) and one (1) product patent from South Korea (10-1707343) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032.The granted claims of the patents are from the mechanism of action include the class of selective H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
